Can I Take Vitamin B12 with Alprostadil (Caverject/MUSE)?

The Short Answer

Vitamin B12 has no known pharmacokinetic or pharmacodynamic interaction with alprostadil in men treated for erectile dysfunction with Caverject, MUSE, or Edex. Alprostadil acts locally on cavernous smooth muscle and is cleared from the systemic circulation within minutes through pulmonary metabolism, while B12 is absorbed through intrinsic factor in the ileum and transported by transcobalamin II, pathways that do not overlap with alprostadil's metabolism or receptor activity. The FDA prescribing information for Caverject does not list vitamins or B12-containing products as an interaction category. The clinically relevant question for many alprostadil users is not whether B12 interacts with alprostadil, but whether metformin, taken separately for diabetes, is lowering their B12 levels.

Why This Question Comes Up

Most men prescribed alprostadil have tried and not responded adequately to oral phosphodiesterase-5 inhibitors (sildenafil, tadalafil), and a substantial share have diabetes-related vascular or neurogenic erectile dysfunction. Metformin is a first-line diabetes medication for this same population. The question "can I take B12 with alprostadil" is often really a question about whether it is safe to take B12 while managing diabetes and erectile dysfunction together. It is safe, and for metformin users it may be advisable, but the reason has little to do with alprostadil itself.

What the Evidence Actually Supports

Established. Alprostadil and vitamin B12 are metabolized through entirely different pathways. Alprostadil is not processed by CYP450 enzymes and is cleared largely by pulmonary oxidation with a plasma half-life on the order of minutes. Vitamin B12 is not a CYP450 substrate, is not displaced from its carrier protein (transcobalamin II) by alprostadil's albumin binding, and has no vasoactive or cyclic-AMP effect that would blunt or potentiate alprostadil's local action on penile smooth muscle. This is consistent with the absence of a vitamin or mineral interaction warning in the Caverject label filed with the FDA.

Plausible but unproven. Vitamin B12 deficiency causes peripheral nerve demyelination, and cavernous nerve integrity contributes to penile sensation and baseline neurovascular tone. It is biologically plausible that correcting a real B12 deficiency could improve a man's baseline erectile physiology, since alprostadil provides pharmacologic vasodilation but does not repair nerve damage. This has not been demonstrated in a trial specific to alprostadil users, so it should be framed as a reasonable hypothesis, not a proven benefit of supplementation.

Not established. There is no evidence that vitamin B12, at any studied dose, changes alprostadil's onset, duration, or required dose. There is also no evidence that B12 supplementation improves erectile response measured objectively in men using alprostadil specifically; most of the supporting literature on B12 and erectile symptoms comes from general diabetic populations, not alprostadil users.

Needs verification before repeating to a patient. The magnitude of metformin's effect on B12 levels is frequently cited with specific numbers (a percentage reduction, an odds ratio for neuropathy, a point difference on an erectile function scale). Those figures originate in specific trials and cohort analyses that should be checked against the primary publication before being stated as fact in patient counseling. This article intentionally avoids repeating precise numbers that could not be re-verified against a specific, correctly identified source at the time of writing.

How Alprostadil Works, and Why B12 Cannot Blunt It

Alprostadil binds prostaglandin EP2 and EP3 receptors on cavernous smooth muscle, raising intracellular cyclic AMP. This activates protein kinase A, which relaxes smooth muscle and allows arterial inflow into the corpus cavernosum. When delivered by intracavernous injection (Caverject, Edex) or as a urethral suppository (MUSE), the effect is largely local, and only a fraction of the dose reaches the systemic circulation before being metabolized.

Vitamin B12 does not inhibit phosphodiesterase, does not compete for prostaglandin receptor binding, and has no effect on cAMP degradation. There is no pharmacodynamic pathway through which B12 could reduce or enhance alprostadil's effect. This mechanistic separation is the basis for saying no interaction exists, rather than simply an absence of reported cases.

The Real Concern for This Population: Metformin and B12

Metformin is widely used in the same men who are candidates for alprostadil, and long-term metformin use has been associated in the literature with reduced vitamin B12 absorption and lower serum B12 over years of treatment. The American Diabetes Association's Standards of Care has, in recent years, recommended that clinicians consider periodic B12 measurement in metformin-treated patients, particularly those with anemia or peripheral neuropathy. ADA Standards of Care, Section 9 covers pharmacologic approaches to glycemic treatment, including this monitoring consideration; readers and clinicians should check the current-year edition for the exact wording and thresholds, since guideline language is updated annually.

This is a metformin-B12 relationship, not an alprostadil-B12 relationship. It matters for alprostadil users only because many of them are also metformin users, and because B12 deficiency neuropathy can overlap in symptoms with diabetic peripheral neuropathy affecting the same nerves involved in erection quality.

Why B12 Status May Matter for Erectile Function Specifically

Alprostadil bypasses the nitric oxide pathway entirely and acts directly on smooth muscle, so it can still produce an erection even when penile nerve conduction is impaired. But erection quality, and the dose of alprostadil needed to achieve a satisfactory result, may be affected by underlying neurovascular health. If a man has untreated B12 deficiency contributing to peripheral neuropathy, correcting the deficiency is a reasonable step to take alongside, not instead of, his alprostadil regimen. This is a plausible clinical rationale rather than a demonstrated outcome specific to alprostadil users.

Pharmacokinetics Side by Side

No shared enzyme, transporter, or receptor has been identified between the two agents. That absence, not a negative study, is the basis for the "no known interaction" conclusion.

Distinguishing Two Kinds of Neuropathy That Get Confused

Both B12 deficiency and diabetic peripheral neuropathy can cause reduced penile sensation and altered erectile response, and patients sometimes attribute these symptoms to their alprostadil regimen rather than to an underlying, treatable nutritional deficiency.

B12 deficiency neuropathy tends to be sensory-predominant and often symmetric. Diabetic neuropathy commonly includes autonomic features as well, such as orthostatic symptoms or bladder dysfunction. A serum B12 test, and in borderline cases a methylmalonic acid or homocysteine level, can help distinguish a deficiency state from progression of diabetic nerve disease. This distinction is a matter for a clinician working from the patient's full history and labs, not something to self-diagnose from symptoms alone.

An Evidence-Status Interaction Assessment

Use this as a structured way to think through the question, and as a checklist for what a clinician or pharmacist should verify rather than assume.

What a Clinician or Pharmacist Should Actually Check

Before framing B12 supplementation as necessary or unnecessary for a specific patient on alprostadil, confirm:

• Whether the patient takes metformin, and at what dose and duration
• Baseline serum B12, with methylmalonic acid or homocysteine if B12 is borderline (roughly 200 to 400 pg/mL, though local lab reference ranges vary)
• Whether neuropathy symptoms are new, progressive, or stable, and whether they predate alprostadil use
• Other risk factors for B12 deficiency: age over 65, history of gastric bypass or atrophic gastritis, strict vegetarian or vegan diet, or use of proton pump inhibitors
• Whether the patient's diabetes team is already monitoring B12 as part of routine metformin follow-up, to avoid duplicate testing

If deficiency is confirmed, standard oral cyanocobalamin repletion regimens exist and are described in the NIH Office of Dietary Supplements B12 fact sheet; a clinician should individualize the dose and form (oral, sublingual, or intramuscular) rather than following a generic protocol, particularly if pernicious anemia or another malabsorption cause is suspected.

Special Populations

Pernicious anemia. Autoimmune loss of intrinsic factor causes severe B12 malabsorption requiring intramuscular or high-dose oral repletion under medical supervision. Alprostadil's pharmacology is unaffected by pernicious anemia, but the neuropathy component can be significant and is often reversible with timely treatment.

Older adults. Atrophic gastritis becomes more common with age and reduces intrinsic factor secretion, which can impair B12 absorption independent of any medication. Broad population surveys such as the CDC's National Health and Nutrition Examination Survey (NHANES) track B12 and related nutrient status over time; a clinician can consult current NHANES data rather than relying on an older cited percentage, since prevalence estimates shift across survey cycles.

Chronic kidney disease. Alprostadil clearance is not substantially affected by renal impairment because pulmonary metabolism dominates its elimination. B12 status can still be assessed with serum B12, but methylmalonic acid can be less reliable as a deficiency marker in significant renal impairment, so homocysteine or clinical correlation may be preferred; this should be confirmed with a clinician managing the patient's kidney disease.

What This Means in Practice

There is no reason to avoid vitamin B12 while using alprostadil, and no timing adjustment is needed between the two. The more useful conversation, for men with diabetes on alprostadil, is with the prescriber managing metformin: whether B12 has been checked recently, and whether neuropathy symptoms warrant a deficiency workup rather than being assumed to be either alprostadil-related or simply part of diabetes progression.

Seek prompt medical attention rather than self-managing if an alprostadil dose produces a prolonged erection lasting more than four hours (priapism), significant penile pain, or a suspected allergic reaction; these are urgent issues unrelated to B12 status.